The GOLGB1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the GOLGB1 gene in a human T lymphocyte model. This polyclonal pool, derived from Jurkat cells, enables investigation of giantin function while maintaining genetic diversity. The knockout disrupts the gene encoding giantin, a critical Golgi membrane protein, providing a robust tool for examining Golgi organization and membrane trafficking in an immune cell context.
Jurkat cells, a human acute T cell leukemia-derived line, grow in suspension and are a cornerstone for T cell receptor (TCR) signaling and adaptive immunity research. Their well-defined signaling pathways and ease of culture make them an ideal host for studying how genetic disruption of GOLGB1 impacts lymphocyte function. This host background ensures that experimental observations are directly relevant to T cell biology and leukemic transformation.
GOLGB1 encodes giantin, a golgin family protein that maintains Golgi stack integrity and tethers COPI vesicles. It interacts with GM130, p115, dynein, and Arf1, and operates within a network involving Rab GTPases and SNARE proteins. GOLGB1 knockout leads to fragmented Golgi, defective vesicular transport, impaired protein glycosylation, and dysregulated cytokine secretion. Consequently, downstream processes such as surface receptor expression are compromised, underscoring the role of giantin in coordinating membrane trafficking and secretory pathway fidelity.
In Jurkat T cells, GOLGB1 disruption offers a model to dissect how Golgi-dependent trafficking controls immune responses. Proper giantin function is required for surface presentation of TCR components, co-receptors, and adhesion molecules, as well as for secretion of cytokines like IL-2. By ablating giantin, researchers can investigate the impact on T cell activation, signaling, and effector functions, linking Golgi biology to adaptive immunity and leukemia pathology.
The polyclonal knockout cells are applicable to diverse studies: Golgi apparatus organization, vesicle-mediated transport, secretory pathway mechanisms, T cell immunology, and cancer biology. They are suitable for assays including western blotting, RT-qPCR, immunofluorescence, flow cytometry, ELISA, cell viability tests, and T cell activation assays. For drug discovery targeting membrane trafficking, these cells provide a physiologically relevant screening platform. For further information, please contact Ascent Research.
